Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial

• Asıl Yazarlar: Guillaume Drevin (Yazar), Marie Briet (Yazar), Caroline Bazzoli (Yazar), Emmanuel Gyan (Yazar), Aline Schmidt (Yazar), Hervé Dombret (Yazar), Corentin Orvain (Yazar), Aurelien Giltat (Yazar), Christian Recher (Yazar), Norbert Ifrah (Yazar), Philippe Guardiola (Yazar), Mathilde Hunault-Berger (Yazar), Chadi Abbara (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2022-04-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optim...